NCT01501084View on ClinicalTrials.gov

Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
Obesity
Interventions
DRUG

Exenatide

10mcg sc (subcutaneous) injection once at one of the 2 MRI visits

DRUG

Normal saline .2cc subcutaneous injection

sterile saline injection

Trial Locations (1)

90095

UCLA Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

University of California, Los Angeles

OTHER